当前位置： SCI文献检索 > PROSTATE CANCER AND PROSTATIC DISEASES期刊下所有文献 > Time course of late rectal toxicity after radiation therapy for prostate cancer.

Time course of late rectal toxicity after radiation therapy for prostate cancer.

Abstract：

:Rectum and bladder are the crucial organs at risk for curative radiation therapy of localized prostate cancer. We analyzed the incidence, profile and time course of late rectal radiation toxicity. A total of 320 patients with T1-3 prostate cancer were treated with three-dimensional conformal radiation therapy (3D-CRT). The prescription dose was 70 Gy for T1 and T2 patients (n=230) and 74 Gy for patients with locally advanced T3 tumors (n=90). Late rectal toxicity was graded according to the Fox Chase modification of the Radiation Therapy Oncology Group (RTOG) and Late Effects Normal Tissue Task Force (LENT) criteria. The median follow-up time was 6.2 years (range 0.2-10.7 years). At 5 years, the risk for the development of grade 2 and 3 rectal toxicities was 15.6 and 7.0%, respectively. All new cases of grade 2 and 3 rectal toxicities were observed within 5 years after treatment. Prevalence of grade 2 and 3 rectal symptoms showed fluctuation with maximum at 1.5 years and the minor peak at 4.5 years. Toxicity profile changed significantly over time. The proportion of rectal bleeding within grade 2 and 3 toxicity decreased from 85% at 1.5 years to 46% at 4.5 years. Conversely, the proportion of fecal incontinence among grade 2 and 3 rectal symptoms gradually increased (0% at 1.5 years vs 27% at 4.5 years). Late rectal radiation toxicity represents a dynamic process. Rectal bleeding decreases and fecal incontinence increases over time.

journal_name

Prostate Cancer Prostatic Dis

journal_title

Prostate cancer and prostatic diseases

authors

Odrazka K,Dolezel M,Vanasek J,Vaculikova M,Zouhar M,Sefrova J,Paluska P,Vosmik M,Kohlova T,Kolarova I,Macingova Z,Navratil P,Brodak M,Prosvic P

doi

10.1038/pcan.2009.56

subject

Has Abstract

pub_date

2010-06-01 00:00:00

pages

138-43

issue

2

eissn

1365-7852

issn

1476-5608

pii

pcan200956

journal_volume

13

pub_type

杂志文章

相关文献

PROSTATE CANCER AND PROSTATIC DISEASES文献大全
  • Novel role for the transient receptor potential channel TRPM2 in prostate cancer cell proliferation.

    abstract：:We have identified a novel function for a member of the transient receptor potential (TRP) protein super-family, TRPM2, in prostate cancer cell proliferation. TRPM2 encodes a non-selective cation-permeable ion channel. We found that selectively knocking down TRPM2 with the small interfering RNA technique inhibited the...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2009.55

    authors： Zeng X,Sikka SC,Huang L,Sun C,Xu C,Jia D,Abdel-Mageed AB,Pottle JE,Taylor JT,Li M

    更新日期：2010-06-01 00:00:00

  • ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.

    abstract：BACKGROUND:Overexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2011.67

    authors： Braun M,Goltz D,Shaikhibrahim Z,Vogel W,Böhm D,Scheble V,Sotlar K,Fend F,Tan SH,Dobi A,Kristiansen G,Wernert N,Perner S

    更新日期：2012-06-01 00:00:00

  • Prevalence of prostatic intra-epithelial neoplasia (PIN) in biopsies from hospital practice and pilot screening: clinical implications.

    abstract：:As high grade PIN is commonly associated with concomitant cancer, current literature recommends re-biopsy of patients with high grade PIN. This paper describes the prevalence of high grade prostatic intra-epithelial neoplasia (PIN) from three independent clinical settings, reported by a single pathologist (MCP). High ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500210

    authors： Feneley MR,Green JS,Young MP,Bose P,Kirby RS,Peeling WB,Parkinson MC

    更新日期：1997-12-01 00:00:00

  • Management of prostate cancer patients during COVID-19 pandemic.

    abstract：:Prostate cancer patients' management demands prioritization, adjustments, and a tailored approach during the unprecedented SARS-CoV-2 pandemic. Benefit of care from treatment must be carefully weighed against the potential of infection and morbidity from COVID-19. Furthermore, urologists need to be cognizant of their ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/s41391-020-0258-7

    authors： Obek C,Doganca T,Argun OB,Kural AR

    更新日期：2020-09-01 00:00:00

  • Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.

    abstract：:Side effects accompanying androgen deprivation therapy (ADT), including sarcopenia, loss of bone mass and reduction in muscle strength, can compromise physical function, particularly in older patients. Exercise, specifically resistance training, may be an effective and cost-efficient strategy to limit or even reverse ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500975

    authors： Galvão DA,Taaffe DR,Spry N,Newton RU

    更新日期：2007-01-01 00:00:00

  • GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome.

    abstract：BACKGROUND:Tumour 18F-FDG-uptake is of prognostic value in high-risk and metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying glucose metabolism mechanisms of 18F-FDG-uptake on PET/CT imaging in PCa. METHODS:Retrospective analysis was conducted for 94 patients diagnosed with a Gleas...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0202-x

    authors： Meziou S,Ringuette Goulet C,Hovington H,Lefebvre V,Lavallée É,Bergeron M,Brisson H,Champagne A,Neveu B,Lacombe D,Beauregard JM,Buteau FA,Riopel J,Pouliot F

    更新日期：2020-09-01 00:00:00

  • Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade.

    abstract：:Antiandrogen therapy is an important modality in the treatment of prostate cancer. Recent research into the role of angiogenesis in tumour growth and metastasis has uncovered links between antiandrogen therapy, radiation therapy and angiogenesis, which have exciting implications for the treatment of prostate cancer. A...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500779

    authors： Woodward WA,Wachsberger P,Burd R,Dicker AP

    更新日期：2005-01-01 00:00:00

  • The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting.

    abstract：INTRODUCTION:Multidisciplinary team (MDT) meetings use precise prognostic factors to select treatment options for patients with prostate cancer. Comorbidity is judged subjectively. Recent publications favour the Charlson comorbidity score (CS) for the use in the management of prostate cancer. We assess the feasibility ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500889

    authors： Kastner C,Armitage J,Kimble A,Rawal J,Carter PG,Venn S

    更新日期：2006-01-01 00:00:00

  • Contemporary management of men with high-risk localized prostate cancer in the United States.

    abstract：BACKGROUND:Surgery and radiation-based therapies are standard management options for men with clinically localized high-risk prostate cancer (PCa). Contemporary patterns of care are unknown. We hypothesize the use of surgery has steadily increased in more recent years. METHODS:Using the National Cancer Data Base for 2...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2017.5

    authors： Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

    更新日期：2017-09-01 00:00:00

  • Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.

    abstract：BACKGROUND:To assess the added value of biopsy factors, like maximum cancer length in a core (MCL), cumulative cancer length (CCL), cumulative length of positive cores (CLPC), percentage of cancer involvement in positive cores (CIPC) and the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria i...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2015.26

    authors： Russo GI,Castelli T,Favilla V,Reale G,Urzì D,Privitera S,Fragalà E,Cimino S,Morgia G

    更新日期：2015-12-01 00:00:00

  • Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study.

    abstract：INTRODUCTION:Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). METHODS:Using prospective multicentre databases of 761 FT and 572 RP cases (November/2005-September/2018), patients with PSA < 20 ng/ml, Gleason <...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-00315-y

    authors： Shah TT,Reddy D,Peters M,Ball D,Kim NH,Gomez EG,Miah S,Evans DE,Guillaumier S,van Rossum PSN,Van Son MJ,Hosking-Jervis F,Dudderidge T,Hindley R,Emara A,McCracken S,Greene D,Nigam R,McCartan N,Valerio M,Minhas S,

    更新日期：2021-01-28 00:00:00

  • Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.

    abstract：:We hypothesized that factors beyond pathological stage, grade, PSA and margin status would be important predictors of biochemical recurrence (BCR) after radical prostatectomy (RP). A cohort of 3194 patients who underwent RP between 1988 and 2007 and who had neither neoadjuvant therapy nor postoperative adjuvant hormon...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2008.18

    authors： Schroeck FR,Sun L,Freedland SJ,Jayachandran J,Robertson CN,Moul JW

    更新日期：2008-01-01 00:00:00

  • Diabetes and prostate cancer risk in the REDUCE trial.

    abstract：:Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to exa...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2011.28

    authors： Wu C,Moreira DM,Gerber L,Rittmaster RS,Andriole GL,Freedland SJ

    更新日期：2011-12-01 00:00:00

  • End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer.

    abstract：BACKGROUND:In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS:Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provi...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2016.67

    authors： Narang AK,Trieu J,Radwan N,Ram A,Robertson SP,He P,Gergis C,Griffith E,Singh H,DeWeese TA,Honig S,Annadanam A,Greco S,DeVille C,McNutt T,DeWeese TL,Song DY,Tran PT

    更新日期：2017-06-01 00:00:00

  • Exposure to direct-to-consumer advertising is associated with overestimation of benefits regarding ultrahypofractionated radiation therapy for prostate cancer.

    abstract：BACKGROUND:While direct-to-consumer (DTC) medical advertising can provide useful information, it also risks oversimplification and being misleading. For an abbreviated prostate cancer treatment regimen called "ultrahypofractionation" (UHF), advertising has been used for CyberKnife (CK), a common delivery system for ste...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0234-2

    authors： Caputo JM,Lee HJ,Chiles B,Hyams ES

    更新日期：2020-12-01 00:00:00

  • Adjuvant and salvage treatment after radical prostatectomy: current practice in the UK.

    abstract：OBJECTIVE:To survey UK urologists and radiation oncologists in the evaluation and treatment of localised prostate cancer in the adjuvant and salvage setting. METHODS:Postal questionnaires were mailed to 292 urologists and 98 radiation oncologists in the UK. RESULTS:In all, 188 (48%) questionnaires were returned. In t...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500816

    authors： Lee LW,Clarke NW,Ramani VA,Cowan RA,Wylie JP,Logue JP

    更新日期：2005-01-01 00:00:00

  • Comparison of outcomes after TURP versus photoselective vaporization of the prostate with respect to trainee involvement utilizing ACS NSQIP.

    abstract：BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究

    doi：10.1038/pcan.2014.13

    authors： Olcese SP,Derosa R,Kern SQ,Lustik MB,Sterbis JR,McMann LP

    更新日期：2014-09-01 00:00:00

  • A prospective randomized comparison of extensive prostate biopsy to standard biopsy with assessment of diagnostic yield, biopsy pain and morbidity.

    abstract：:In a prospective randomized study, we compare standard prostate biopsy to extensive biopsy utilizing intravenous conscious sedation (IVCS). Initial biopsy patients (n=197) were randomized to either standard biopsy using intrarectal lidocaine gel (6-12 biopsies, mean 10.1) or extensive biopsy (24 biopsies) using IVCS. ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.pcan.4500713

    authors： Sur RL,Borboroglu PG,Roberts JL,Amling CL

    更新日期：2004-01-01 00:00:00

  • Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.

    abstract：BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0224-4

    authors： Du M,Tian Y,Tan W,Wang L,Wang L,Kilari D,Huang CC,Wang L,Kohli M

    更新日期：2020-12-01 00:00:00

  • Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?

    abstract：:The relationships between serum level of testosterone (T) and prostate cancer (PCa) are complex. The present study evaluated whether presence of PCa alters serum T levels. Subjects were 125 patients with clinically localized PCa treated using radical prostatectomy (RP), for whom pretreatment T levels were recorded. We...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2008.35

    authors： Imamoto T,Suzuki H,Yano M,Kawamura K,Kamiya N,Araki K,Komiya A,Naya Y,Shiraishi T,Ichikawa T

    更新日期：2009-01-01 00:00:00

  • A review of pomegranate in prostate cancer.

    abstract：BACKGROUND:Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials. METH...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/pcan.2017.19

    authors： Paller CJ,Pantuck A,Carducci MA

    更新日期：2017-09-01 00:00:00

  • Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study.

    abstract：:A series of 212 prostate specimens of men dead between August 2002-August 2004, have been sectioned in consecutive autopsies and subjected to whole mount analysis in purpose to determine the epidemiology of impalpable prostate cancer in Greece. Impalpable prostate carcinomas were found in 40 cases (18.8%) most in the ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500847

    authors： Stamatiou K,Alevizos A,Perimeni D,Sofras F,Agapitos E

    更新日期：2006-01-01 00:00:00

  • A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer.

    abstract：BACKGROUND:Focal therapy is an emerging mini-invasive treatment modality for localized prostate cancer aimed to reduce the morbidity associated with radical therapy while maintaining optimal cancer control. We report the mid-term oncological and functional results of primary hemiablation high-intensity focused ultrasou...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 临床试验,杂志文章

    doi：10.1038/pcan.2015.55

    authors： van Velthoven R,Aoun F,Marcelis Q,Albisinni S,Zanaty M,Lemort M,Peltier A,Limani K

    更新日期：2016-03-01 00:00:00

  • Active surveillance for intermediate-risk prostate cancer.

    abstract：BACKGROUND:Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low- or low-risk disease. We sought to review the current experience with AS for men with int...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,meta分析,评审

    doi：10.1038/pcan.2016.51

    authors： Dall'Era MA,Klotz L

    更新日期：2017-03-01 00:00:00

  • Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer.

    abstract：BACKGROUND:Tumor contact length (TCL) is defined as the extent of contact between prostate cancer and the prostatic capsule, and its predictive value for microscopic extraprostatic extension (EPE) has been reported. However, the impact of the zonal origin (anterior or posterior tumor) of the tumor on the diagnosis of E...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-019-0136-3

    authors： Matsumoto K,Akita H,Narita K,Hashiguchi A,Takamatsu K,Takeda T,Kosaka T,Mizuno R,Kikuchi E,Oya M,Jinzaki M

    更新日期：2019-12-01 00:00:00

  • Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer.

    abstract：BACKGROUND:Heat shock protein 27 (Hsp-27) encoded by gene HSPB1 is a critical regulator of the behavioral phenotype of human prostate cancer (PCa) cells, enhanced expression being associated with highly aggressive disease and poor clinical outcome. In contrast, the protein is not expressed in PCas of low malignant pote...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2012.47

    authors： Vasiljević N,Ahmad AS,Beesley C,Thorat MA,Fisher G,Berney DM,Møller H,Yu Y,Lu YJ,Cuzick J,Foster CS,Lorincz AT

    更新日期：2013-03-01 00:00:00

  • Histopathological findings after radiofrequency (RITA) treatment for prostate cancer.

    abstract：:Radiofrequency interstitial tumor ablation (RITA) is a thermal ablation method that uses needles and low radiofrequency (RF) energy. The aim of our study was to evaluate the histopathology of thermal lesions induced by RF energy delivered interstitially in prostate cancer patients who subsequently underwent prostatect...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500877

    authors： Patriarca C,Bergamaschi F,Gazzano G,Corrada P,Ordesi G,Zanitzer L,Di Pasquale M,Giunta P,Campo B

    更新日期：2006-01-01 00:00:00

  • High-intensity interval training produces a significant improvement in fitness in less than 31 days before surgery for urological cancer: a randomised control trial.

    abstract：OBJECTIVES:To assess the efficacy of high-intensity interval training (HIIT) for improving cardiorespiratory fitness (CRF) in patients awaiting resection for urological malignancy within four weeks. SUBJECTS/PATIENTS AND METHODS:A randomised control trial of consecutive patients aged (>65 years) scheduled for major ur...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0219-1

    authors： Blackwell JEM,Doleman B,Boereboom CL,Morton A,Williams S,Atherton P,Smith K,Williams JP,Phillips BE,Lund JN

    更新日期：2020-12-01 00:00:00

  • Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.

    abstract：BACKGROUND:The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long nonco...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/pcan.2015.48

    authors： Mouraviev V,Lee B,Patel V,Albala D,Johansen TE,Partin A,Ross A,Perera RJ

    更新日期：2016-03-01 00:00:00

  • Contemporary management of men with high-risk localized prostate cancer in the United States.

    abstract：:This corrects the article DOI: 10.1038/pcan.2017.5. ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,已发布勘误

    doi：10.1038/pcan.2017.35

    authors： Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

    更新日期：2017-12-01 00:00:00